15 results about "Bifunctional Antibodies" patented technology

An anti-CTLA4 (cytotoxic T lymphocyte associated antigen 4) and anti-PD-1 (programmed cell death 1) bifunctional antibody. a pharmaceutical composition thereof and use thereof. Particularly, the anti-CLTA4 and anti-PD-1 bifunctional antibody comprises a first protein functional domain that targets PD-1 and a second protein functional domain that targets CTLA-4. The bifunctional antibody can bind to CTLA-4 and PD-1 specifically, relieve immunosuppression of CTLA4 and PD-1 on an organism specifically, activate T lymphocytes, and thus has good application prospects.

The present application relates to the fields of tumor treatment and molecular immunology, and specifically, to an anti-VEGFA / PD-1 bifunctional antibody, a pharmaceutical composition thereof and use thereof. Specifically, the anti-VEGFA / PD-1 bifunctional antibody comprises an antibody or antigen binding fragment thereof targeting VEGFA and an antibody or antigen binding fragment thereof targeting PD-1. The bifunctional antibody can specifically bind to VEGFA and PD-1, specifically relieve immunosuppression of VEGFA and PD-1 in an organism, and inhibit tumor-induced angiogenesis.

The present application relates to an anti-PD-1 and OX-40 bifunctional antibody and a preparation method and application thereof. The bifunctional antibody comprises an antibody domain targeting PD-1 and an antibody domain targeting OX-40. The present application designs a novel anti-PD-1 / OX-40 bifunctional antibody, constructs a specific structure bifunctional antibody by using a PD-1 activating antibody and an OX-40 blocking antibody, and the whole synergizes, has high affinity to PD-1, can activate PD-1 activity and its signal pathway, has high affinity to OX40, can block OX40 / OX40L interaction and its signal transduction, inhibits T cell proliferation, inhibits CD25 or PD-1 positive CD4 + T cell production can be applied to the development of related drugs for treating inflammatory or autoimmune diseases.

The application relates to a hepcidin chemiluminescence immunoassay kit and a non-diagnostic method for detecting hepcidin, the kit comprising a calibrator, a quality control, an integrated bifunctional antibody reagent, a magnetic particle reagent, a cleaning solution and a chemiluminescence substrate solution; the integrated bifunctional antibody reagent is a buffer containing HEP-specific antibodies covalently connected with fluorescein isothiocyanate and alkaline phosphatase through pH-sensitive connecting bonds; the magnetic particle reagent is a magnetic microsphere suspension coated with a goat anti-fluorescein isothiocyanate antibody; the cleaning solution is a buffer containing a surfactant composition, and the surfactant composition comprises nonionic surfactants, zwitterionic surfactants and high-molecular nonionic surfactants. The hepcidin chemiluminescence immunoassay kit has the effects of ultra-low background noise, ultra-high sensitivity, ultra-wide linear range and simplified operation of end users by means of the integrated bifunctional antibody reagent and the surfactant composition cleaning solution.

The invention belongs to the technical field of antibodies, and relates to a bifunctional antibody targeting PD-L1 and sialic acid as well as a preparation method and application of the bifunctional antibody. The invention provides a bifunctional antibody targeting PD-L1 and sialic acid, the bifunctional antibody has PD-L1 binding activity and sialic acid hydrolytic activity, the structure of the bifunctional antibody comprises a nano antibody Nb16 combined with mouse PD-L1, a connecting peptide and sialidase SiaT, and the N end of the sialidase is connected with the C end of the PD-L1 nano antibody through the connecting peptide. The bifunctional antibody fused by the PD-L1 nano antibody (Nb16) and sialidase (SiaT) has the function of blocking PD-1 / PD-L1 signal transmission and the function of hydrolyzing sialic acid on the surface of a cell, and can effectively play an anti-tumor role in vivo.

The invention provides a bifunctional antibody or antigen binding fragment, the Fab end of the bifunctional antibody or antigen binding fragment can target B cells, and the Fc end of the bifunctional antibody or antigen binding fragment enhances the binding affinity to FcRn protein through amino acid mutation. The antibody can achieve the effect of treating autoimmune diseases through different action mechanisms, and the treatment effect of the antibody is superior to that of existing single-target-point targeting drugs.

The invention belongs to the technical field of antibodies, and relates to a bifunctional antibody targeting PD-L1 and sialic acid as well as a preparation method and application of the bifunctional antibody. The invention provides a bifunctional antibody targeting PD-L1 and sialic acid, the bifunctional antibody has PD-L1 binding activity and sialic acid hydrolytic activity, the structure of the bifunctional antibody comprises a nano antibody Nb16 combined with mouse PD-L1, a connecting peptide and sialidase SiaT, and the N end of the sialidase is connected with the C end of the PD-L1 nano antibody through the connecting peptide. The bifunctional antibody fused by the PD-L1 nano antibody (Nb16) and sialidase (SiaT) has the function of blocking PD-1 / PD-L1 signal transmission and the function of hydrolyzing sialic acid on the surface of a cell, and can effectively play an anti-tumor role in vivo.

The invention discloses a nano adapter for cooperatively enhancing natural killer cell immunotherapy in combination with Vickers and application, and belongs to the crossing field of biological medicine and nanotechnology. According to the invention, the nanoparticles are prepared through coprecipitation of excipient molecules and Venoclara, the drug hydrophobicity is improved, and space-time synergy of chemotherapeutic drugs and immune cell therapy is realized through immune activation-target blocking bifunctional antibody modification. The invention has great application potential in clinical and scientific research fields such as research and development of anti-hematological malignant tumor drugs, drug effect research, leukemia cell drug resistance research and the like.

The present application relates to a bifunctional antibody against PD-1 and TNF alpha and a preparation method and application thereof. The bifunctional antibody comprises an antibody domain targeting PD-1 and an antibody domain targeting TNF alpha. The present application provides a bifunctional antibody with high affinity to PD-1, capable of activating the activity and signal pathway of PD-1, and with high affinity to TNF alpha, capable of blocking the interaction and signal transduction of TNF alpha / TNFR, which can be applied to the development of related drugs for treating inflammatory or autoimmune diseases.

The application discloses an anti-red blood cell membrane antibody and application thereof, and relates to a heavy chain and a light chain, wherein the amino acid sequence of the variable region of the heavy chain is shown as SEQ ID NO:1, or is a conservative mutant obtained by adding, deleting, replacing or modifying one or more amino acids of the sequence; the amino acid sequence of the variable region of the light chain is shown as SEQ ID NO:2, or is a conservative mutant obtained by adding, deleting, replacing or modifying one or more amino acids of the sequence; the sequences of CDR1, CDR2 and CDR3 of the variable region of the heavy chain are shown as SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5; the sequences of CDR1, CDR2 and CDR3 of the variable region of the light chain are shown as SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8; and the anti-red blood cell membrane antibody is used in the construction of a bifunctional antibody reagent. The anti-red blood cell membrane antibody is used in chromatography detection, and rbc can be intercepted on a sample pad by processing on the sample pad, so that whole blood can be detected.

A polypeptide is provided comprising, from N- to C-terminus, a) at least one heavy chain variable region of a heavy chain antibody that binds Programmed Death-Ligand 1 (PD-L1) (VHH domain) operably linked to an IgG Fc binding domain; and b) human TGFβRII or a fragment thereof capable of binding TGFβ. Also provided are antibodies comprising the polypeptide, amino acid sequences of the antibodies, cloning or expression vectors, cells, and methods for expressing or isolating the antibodies. Also provided are therapeutic compositions comprising the antibodies, and methods of treating cancer and other diseases with the bispecific antibodies.

The present application provides a bispecific antibody targeting PD-L1 and FasL, which comprises: (a) a PD-L1 antibody capable of specifically binding to PD-L1, and (b) a FasL antibody or a Fas extracellular domain, a truncated or mutant of the Fas extracellular domain, capable of specifically binding to FasL; wherein the heavy chain variable region and the light chain variable region of the FasL antibody are connected to the heavy chain variable region and the light chain variable region of the PD-L1 antibody through a linker sequence, and / or the Fas extracellular domain is connected to the constant region of the PD-L1 antibody through a linker sequence. The present application comprises a preparation method of the molecule and its use as an anticancer drug. The bispecific antibody of the present application comprises a fragment capable of binding to PD-L1 and a fragment specifically binding to FasL, and such bifunctional antibody molecule can produce a synergistic effect and play a high-efficiency antitumor role. Compared with the administration of either of the two antibodies alone, the bispecific antibody of the present application shows a significant synergistic effect in cancer therapy.

The invention relates to the technical field of biology, in particular to a bifunctional antibody for promoting wound healing reaction and a pharmaceutical composition thereof, at least comprising: a first protein functional region targeting CD4, the first protein functional region being an anti-CD4 antibody or an antigen binding fragment thereof; a second protein functional region, the second protein functional region targeting TGF [beta] 1 / [beta] 2 (especially not targeting TGF [beta] 3), the second protein functional region being an anti-TGF [beta] 1 / [beta] 2 (especially not anti-TGF [beta] 3) antibody or an antigen binding fragment thereof; the double antibody can be safely combined with CD4, but the function of the CD4 is not influenced; by combining with CD4, the double antibody can specifically inhibit a TGF-beta1 signal of CD4 + T cells, so that the inhibition effect of TGF-beta1 on the CD4 + T cells is relieved, and the wound healing reaction mediated by the TGF-beta1 is released; meanwhile, the double antibodies can inhibit TGF-beta2 so as to inhibit the fibrosis promotion capability of the TGF-beta2, and have no inhibition capability on TGF-beta3, so that the wound healing promotion capability of the double antibodies is reserved, and the double antibodies can be used for reducing the scar area after wound healing.

The invention belongs to the technical field of antibodies, and relates to a bifunctional antibody targeting PD-L1 and sialic acid as well as a preparation method and application of the bifunctional antibody. The invention provides a bifunctional antibody targeting PD-L1 and sialic acid, the bifunctional antibody has PD-L1 binding activity and sialic acid hydrolytic activity, the structure of the bifunctional antibody comprises a nano antibody Nb16 combined with mouse PD-L1, a connecting peptide and sialidase SiaT, and the N end of the sialidase is connected with the C end of the PD-L1 nano antibody through the connecting peptide. The bifunctional antibody fused by the PD-L1 nano antibody (Nb16) and sialidase (SiaT) has the function of blocking PD-1 / PD-L1 signal transmission and the function of hydrolyzing sialic acid on the surface of a cell, and can effectively play an anti-tumor role in vivo.

The present invention relates to the technical field of biology, particularly to a bifunctional antibody for treating systemic sclerosis and a pharmaceutical composition thereof, the bifunctional antibody at least comprises: a first protein functional region targeting CD4, the first protein functional region being an anti-CD4 antibody or an antigen binding fragment thereof; the second protein functional region is targeted to TGF [beta] 1 / [beta] 2 / [beta] 3, and the second protein functional region is an anti-TGF [beta] 1 / [beta] 2 / [beta] 3 antibody or an antigen binding fragment of the anti-TGF [beta] 1 / [beta] 2 / [beta] 3 antibody; the double antibody can be safely combined with CD4, but the function of the CD4 is not influenced; through combination with CD4, the double antibody can specifically inhibit a TGF-beta1 signal of CD4 + T cells, so that the inhibition effect of TGF-beta1 on the CD4 + T cells is relieved, and a tissue repair reaction mediated by the TGF-beta1 is released; meanwhile, the double antibodies can inhibit TGF-beta2 and TGF-beta3, so that the fibrosis promoting capability of the double antibodies is inhibited, and the double antibodies can be used for treating systemic sclerosis.